About Differentia

We believe critical life science decisions should be simulated before they are committed to the real world.

Drug development requires a series of high-stakes decisions—what to develop, how to develop it, where to invest, and ultimately how to treat each patient. Today, many of these decisions are still made through sequential experimentation, with increasing costs, time and uncertainty.

Our thesis is simple: Simulate first. Then test in the real world.

Differentia is building the decision intelligence infrastructure for life sciences—combining AI with mechanistic modeling to turn complex biological questions into testable virtual experiments.

One scientific foundation. Three decision domains.

R&D

Identify the best targets, molecules, dosing strategies, trials and patient populations.

Capital

Connect scientific evidence to asset prioritization, portfolio strategy, investment, licensing and M&A decisions.

Clinical

Over time, extend mechanistic digital twins toward precision medicine and individualized treatment decisions.

As evidence accumulates across the lifecycle of an asset, the same underlying intelligence can inform more decisions—creating compounding value from R&D to capital to clinical care.

  • AI-Powered
  • Mechanistic
  • Validated
  • Regulatory-Ready

Why Differentia

Mechanistic intelligence for decisions that matter.

Human Mechanistic Digital Twins
Model the biology that matters.

Integrate multi-omics data into disease biology, drug action and patient response.

Not just prediction. Testable biological hypotheses.
Decision-Ready AI
Accelerate science without hiding the logic.

AI orchestrates virtual experiments to test scenarios and answer “what if?”

Virtual Experiments · Scenario Simulation
Regulatory-Ready by Experience
Built by Industry and Scientific Leaders

Decades of expertise spanning global pharma, clinical development, biosimulation modeling and regulatory science.

Scientific rigor. FDA/EMA Aligned - Submission-ready evidence.

Human Mechanistic Digital Twins

Model the biology that matters.

Integrate multi-omics data into disease biology, drug action and patient response.

Not just prediction. Testable biological hypotheses.

Decision-Ready AI

Accelerate science without hiding the logic.

AI orchestrates virtual experiments to test scenarios and answer “what if?”

Virtual Experiments · Scenario Simulation

Regulatory-Ready by Experience

Built by Industry and Scientific Leaders

Decades of expertise spanning global pharma, clinical development, biosimulation modeling and regulatory science.

Scientific rigor. FDA/EMA Aligned - Submission-ready evidence.

2023
Founded
200+
Team project experience
7,000+
Publication citations
Global
Pharma - Biotech - CROs - Capital

Leadership

Industry & Scientific Leaders

Kalyanasundaram (Kas) Subramanian, PhD

Kalyanasundaram (Kas) Subramanian, PhD

Co-Founder and Chief Executive Officer

AI, computational biology, and quantitative biosciences leader with a track record of building scientific platforms and pioneering simulation-driven drug development.

Atefeh Kazeroonian, PhD

Atefeh Kazeroonian, PhD

VP, Mechanistic Modeling

Computational immunologist and AI researcher specializing in systems biology, mathematical modeling, and complex disease mechanisms

Catherine Sherwin, PhD

Catherine Sherwin, PhD

Chief Regulatory & Clinical Pharmacology Officer

Internationally recognized scientist combining regulatory sciences, clinical pharmacology, and AI-powered virtual clinical trials.

Dariush Mohammadyani, PhD

Dariush Mohammadyani, PhD

VP, Commercial

Computational biophysicist and pharmaceutical R&D leader bridging computational-driven research and global industry partnerships

Rajeev Kumar, PhD

Rajeev Kumar, PhD

Senior Director, Mechanistic Modeling

Computational scientist specializing in mechanistic AI, mathematical modeling, and systems pharmacology

Simon Junankar, PhD

Simon Junankar, PhD

Director, Scientific Affairs

Cancer biology and immunology scientist integrating multi-omics data, advanced computational methods, and translational disease research